Kelsey Hogan

Impact of Tardive Dyskinesia on Psychological and Social Aspects of Patient Lives: A Survey of Patients and Caregivers in the United States

Abstract: Background: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that substantially impacts patients’ lives. This study assessed psychological and social aspects of TD fr...

Stacy Finkbeiner ;

Kelsey Hogan ;

01/19/2023

Long-Term Efficacy and Safety of Deutetrabenazine in Postmenopausal Women With Tardive Dyskinesia

Abstract: Introduction: Advanced age and female sex are risk factors for tardive dyskinesia (TD). This post hoc analysis assessed the long-term efficacy and safety of deutetrabenazine, an...

Stacy Finkbeiner ;

Kelsey Hogan ;

01/19/2023

Tardive Dyskinesia: Epidemiological Trends in US Populations Based on Cross-Sectional Analysis of Retrospective Claims Data

Abstract: Background: Tardive dyskinesia (TD), an iatrogenic movement disorder associated with antipsychotic agent (AP) use, is predicted to increase in prevalence, but real-world data ar...

Pooja Gandhi ;

Kelsey Hogan ;

01/19/2023

Understanding the Use of Long-Acting Injectable Antipsychotic Agents in Schizophrenia: A 2022 Survey of US Psychiatrists, Nurse Practitioners, and Physician Associates

Abstract: Background: Treatment with long-acting injectable antipsychotic agents (LAIs) has been shown to improve outcomes in schizophrenia; however, many healthcare providers continue to...

Kelsey Hogan ;

Rolf T. Hansen , PhD;

01/19/2023

Impact of Tardive Dyskinesia on Physical Aspects of Patient Lives: A Survey of Patients and Caregivers in the United States

Abstract: Background: Tardive dyskinesia (TD) substantially impacts patients’ ability to function in their daily lives. This study assessed physical functioning of patients with TD from t...

Kelsey Hogan ;

Sam Leo ;

01/19/2023

Influence of Cultural Differences and Genetic Polymorphisms on Schizophrenia Management: An Exploratory Targeted Literature Review

Abstract: Objective: Cultural differences impact schizophrenia management across countries and may complicate the evaluation of new therapeutics. Genetic polymorphisms are associated with...

Marko Mychaskiw , PhD;

Kelsey Hogan ;

01/19/2023

Clinical Dilemmas in Schizophrenia Treatment and the Potential Place in Therapy of Long-acting Antipsychotic Agents

Abstract: Introduction: Treatment nonadherence in schizophrenia is a continuing challenge, but can be improved with use of long-acting injectable antipsychotic agents (LAIs). Although wel...

Marko Mychaskiw , PhD;

Kelsey Hogan ;

01/19/2023

Introducing S.C.O.P.E.™: Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement—An Interactive Digital Platform to Educate on Schizophrenia Care

Abstract: Introduction: Healthcare professionals (HCPs) face unique challenges when managing patients with schizophrenia. Educational initiatives targeting the most common dilemmas encoun...

Marko Mychaskiw , PhD;

Kelsey Hogan ;

01/19/2023

Dispelling Myths and Misconceptions Surrounding the Use of Long-acting Injectable Antipsychotic Agents for Treatment of Schizophrenia

Abstract: Introduction: Schizophrenia affects over 3 million people in the United States. Despite data supporting the use of long-acting injectable antipsychotic agents (LAIs), myths and ...

Marko Mychaskiw , PhD;

Kelsey Hogan ;

01/19/2023

IMPACT-TD Registry: Real-World Assessment of the Impact and Progression of Tardive Dyskinesia

Abstract: Background: The long-term impact, burden, and treatment patterns of tardive dyskinesia (TD) are not well understood. Patient- and clinician-reported outcomes are important in de...

Kelsey Hogan ;

Martijn Konings ;

01/19/2023